(Q37967508)

26 August 2017

title

Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology (English)

1 reference

26 August 2017

1 reference

1

1 reference

26 August 2017

2

1 reference

26 August 2017

language of work or name

1 reference

13 December 2011

1 reference

Internal and emergency medicine

26 August 2017

published in

1 reference

26 August 2017

volume

7

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

113-131

1 reference

Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

The hERG K+ channel: target and antitarget strategies in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Pharmacological foundations of cardio-oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Adverse effects of anticancer agents that target the VEGF pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Mechanisms of hypertension associated with BAY 43-9006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Management of hypertension in angiogenesis inhibitor-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Diagnosis of heart failure in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Cardiovascular toxicity caused by cancer treatment: strategies for early detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Role of biomarkers in chemotherapy-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Adjuvant targeted therapy in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Cardiotoxicity profile of trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Congestive heart failure is a rare event in patients receiving imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

An evaluation of the cardiotoxicity of imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Severe peripheral arterial disease during nilotinib therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Selective antagonism of anticancer drugs for side-effect removal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Management of trastuzumab-related cardiac dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Thrombotic events in patients with cancer receiving antiangiogenesis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-011-0744-Y

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

21 January 2018

1 reference

12 December 2020

Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials

1 reference

12 December 2020

Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes

1 reference

12 December 2020

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

1 reference

12 December 2020

Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials

1 reference

12 December 2020

A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib

1 reference

12 December 2020

Troponin I Provides Insight Into Cardiotoxicity and the Anthracycline-Trastuzumab Interaction

1 reference

12 December 2020

Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab

1 reference

12 December 2020

Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and

1 reference

12 December 2020

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

1 reference

12 December 2020

Diet-derived phytochemicals: from cancer chemoprevention to cardio-oncological prevention

1 reference

12 December 2020

Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?

1 reference

12 December 2020

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

1 reference

12 December 2020

Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer

1 reference

12 December 2020

10.1007/S11739-011-0744-Y

Identifiers

DOI

1 reference

26 August 2017

1 reference